Lancet 366:12791289 Dozio E, Vianello E, Malavazos AE, Tacchini L, Schmitz G, Iacobellis G, Corsi Romanelli MM (2019) Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk
35 Comparative prevalence rates are as follows: 16.6% in Australia, 36 48% in Finland with a gender-specific breakdown of 60% in males and 31% in females, 37 17.0% in New Zealand with 27.8% in males and 8.8% in females, 38 24.5% in Ireland with 25.0% in males and 24.1% in females, 39 9.9% in Croatia, 40 16.8% in Russia, 41 12.1% in Turkey with 19.0% in male and 5.8% in female, 42 21.2% in Qatar
NICE has published technology appraisals for licensed GLP-1-based medicines used in weight management, including TA875 (semaglutide 2.4 mg for managing overweight and obesity)
The FDA and the U.K.s Medicines and Healthcare Products Regulatory Agency (MHRA) have both issued warnings about counterfeit medications
Biochemical pathways linking adiposity, diet, and endometrial carcinogenesis
no reported serious adverse effects at research doses
